請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78335
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂(Jin-Town Wang) | |
dc.contributor.author | Yen-Hao Chen | en |
dc.contributor.author | 陳彥豪 | zh_TW |
dc.date.accessioned | 2021-07-11T14:51:47Z | - |
dc.date.available | 2025-08-04 | |
dc.date.copyright | 2020-09-10 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-04 | |
dc.identifier.citation | 1. Friedlaender, C.J.A.f.p.A.u.P.u.f.k.M., Ueber die Schizomyceten bei der acuten fibrösen Pneumonie. 1882. 87(2): p. 319-324.
2. Rock, C., et al., Frequency of Klebsiella pneumoniae carbapenemase (KPC)-producing and non-KPC-producing Klebsiella species contamination of healthcare workers and the environment. Infect Control Hosp Epidemiol, 2014. 35(4): p. 426-9. 3. Bagley, S.T., Habitat association of Klebsiella species. Infect Control, 1985. 6(2): p. 52-8. 4. Struve, C. and K.A. Krogfelt, Role of capsule in Klebsiella pneumoniae virulence: lack of correlation between in vitro and in vivo studies. FEMS Microbiol Lett, 2003. 218(1): p. 149-54. 5. Dao, T.T., et al., Klebsiella pneumoniae oropharyngeal carriage in rural and urban Vietnam and the effect of alcohol consumption. PLoS One, 2014. 9(3): p. e91999. 6. Wang, J.H., et al., Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis, 1998. 26(6): p. 1434-8. 7. Siu, L.K., et al., Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis, 2012. 12(11): p. 881-7. 8. Follador, R., et al., The diversity of Klebsiella pneumoniae surface polysaccharides. Microb Genom, 2016. 2(8): p. e000073. 9. Pan, Y.J., et al., Genetic analysis of capsular polysaccharide synthesis gene clusters in 79 capsular types of Klebsiella spp. Sci Rep, 2015. 5: p. 15573. 10. Spellberg, B., et al., Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis, 2011. 52 Suppl 5: p. S397-428. 11. Vardakas, K.Z., et al., Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect, 2013. 66(5): p. 401-14. 12. van Duin, D. and D.L. Paterson, Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. Infect Dis Clin North Am, 2016. 30(2): p. 377-390. 13. Munoz-Price, L.S., Extended-spectrum beta-lactamases. 14. Rawat, D. and D. Nair, Extended-spectrum beta-lactamases in Gram Negative Bacteria. J Glob Infect Dis, 2010. 2(3): p. 263-74. 15. Lin, W.P., et al., The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis. Sci Rep, 2016. 6: p. 36280. 16. Papp-Wallace, K.M., et al., Carbapenems: past, present, and future. Antimicrob Agents Chemother, 2011. 55(11): p. 4943-60. 17. CDC, Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014. 18. Samuelsen, O., et al., Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother, 2009. 63(4): p. 654-8. 19. Breurec, S., et al., Klebsiella pneumoniae resistant to third-generation cephalosporins in five African and two Vietnamese major towns: multiclonal population structure with two major international clonal groups, CG15 and CG258. Clin Microbiol Infect, 2013. 19(4): p. 349-55. 20. CDC, T., Annual Report of Nosocomial Infections Surveillance System(2016). 2016. 21. Gupta, N., et al., Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis, 2011. 53(1): p. 60-7. 22. Gupta, S., et al., Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med, 2009. 13(2): p. 49-53. 23. Gregoire, N., et al., Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin Pharmacokinet, 2017. 56(12): p. 1441-1460. 24. Liu, Y.Y., et al., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis, 2016. 16(2): p. 161-8. 25. Slover, C.M., K.A. Rodvold, and L.H. Danziger, Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother, 2007. 41(6): p. 965-72. 26. Dixit, D., R.P. Madduri, and R. Sharma, The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther, 2014. 12(4): p. 397-400. 27. Ruzin, A., et al., Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2005. 49(3): p. 1017-22. 28. Silver, L., Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening. 2012. p. 33-75. 29. Zhu, J.Y., et al., Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). J Biol Chem, 2012. 287(16): p. 12657-67. 30. Patel, S.S., J.A. Balfour, and H.M. Bryson, Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs, 1997. 53(4): p. 637-56. 31. Trapnell, B.C., et al., Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med, 2012. 185(2): p. 171-8. 32. Dijkmans, A.C., et al., Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel), 2017. 6(4). 33. Castañeda-García, A., J. Blázquez, and A. Rodríguez-Rojas, Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel, Switzerland), 2013. 2(2): p. 217-236. 34. Brown, D.W., et al., Evolution of the antibiotic resistance protein, FosA, is linked to a catalytically promiscuous progenitor. Biochemistry, 2009. 48(9): p. 1847-1849. 35. Zeng, G., S. Ye, and T.J. Larson, Repressor for the sn-glycerol 3-phosphate regulon of Escherichia coli K-12: primary structure and identification of the DNA-binding domain. J Bacteriol, 1996. 178(24): p. 7080-9. 36. Dahl, J.L., B.Y. Wei, and R.J. Kadner, Protein phosphorylation affects binding of the Escherichia coli transcription activator UhpA to the uhpT promoter. J Biol Chem, 1997. 272(3): p. 1910-9. 37. Sakamoto, Y., et al., Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem, 2003. 67(9): p. 2030-3. 38. Tuon, F.F., et al., Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil. J Infect, 2013. 67(3): p. 247-9. 39. Kaase, M., et al., Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol, 2014. 52(6): p. 1893-7. 40. Endimiani, A., et al., In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother, 2010. 54(1): p. 526-9. 41. Jiang, Y., et al., Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents, 2015. 45(1): p. 66-70. 42. Tseng, S.P., et al., The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan. J Microbiol Immunol Infect, 2017. 50(5): p. 653-661. 43. Lu, P.L., et al., Characterisation of fosfomycin resistance mechanisms and molecular epidemiology in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates. Int J Antimicrob Agents, 2016. 48(5): p. 564-568. 44. Humphries, R.M., et al., CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J Clin Microbiol, 2018. 56(4). 45. Organization, W.H., 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. 2019. 46. Candel, F.J., M. Matesanz David, and J. Barberan, New perspectives for reassessing fosfomycin: applicability in current clinical practice. Rev Esp Quimioter, 2019. 32 Suppl 1: p. 1-7. 47. Karaiskos, I., et al., The 'Old' and the 'New' Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front Public Health, 2019. 7: p. 151. 48. Cao, X.L., et al., High prevalence of fosfomycin resistance gene fosA3 in bla CTX-M-harbouring Escherichia coli from urine in a Chinese tertiary hospital during 2010-2014. Epidemiol Infect, 2017. 145(4): p. 818-24. 49. Law, C.J., P.C. Maloney, and D.N. Wang, Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol, 2008. 62: p. 289-305. 50. Ito, R., et al., Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. Antimicrob Agents Chemother, 2017. 61(12). 51. Liu, P., et al., Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2020. 22: p. 238-243. 52. Hsieh, P.F., et al., Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis, 2008. 197(12): p. 1717-27. 53. Green, M.R., J. Sambrook, and J. Sambrook, Molecular cloning : a laboratory manual. 4th ed. 2012. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78335 | - |
dc.description.abstract | 磷黴素(fosfomycin)是早期用以治療泌尿道感染的抗生素,近年來本來已較少使用。但由於現今多重抗藥性(Mμltidrμg-resistant;MDR)菌株的肆虐,在後線藥物逐漸失效的情況下,便將磷黴素合併使用其他抗生素作為多重抗藥性菌株治療。然而臨床上也漸漸出現對磷黴素產生抗藥性的菌株,本研究針對台北榮民總醫院臨床分離出56 株碳青黴烯類類抗生素之克雷伯氏肺炎桿菌(carbapenem-resistant Klebsiella pneumoniae;CRKP)先以磷黴素濃度為256 μg/ml做初步篩選後,再進一步以濃度0-2048 μg/ml進行最小抑菌濃度(Minimal inhibitory concentration;MIC)分析,結果發現其中有19 株為對磷黴素高抗藥性(MIC≧1024 μg/ml)。將此19株臨床菌株做磷黴素抗藥性相關基因之定序分析,結果發現共有12株具有甘油-3-磷酸運輸蛋白質(glycerol-3-phosphate transporter;glpT) 基因突變;9株具有葡萄糖-6-磷酸運輸蛋白質(glucose-6-phosphate transporter;uhpT)基因突變;4株菌株於調節蛋白質(glpR, uhpA, uhpB, uhpC,ptsI, cyaA)相關基因上帶有突變或缺失。在運輸蛋白質功能測試(Transporter functional assay)有11 株在甘油-3-磷酸(glycerol-3-phosphate;G3P)M9 培養基生長較差,10 株在葡萄糖-6-磷酸運輸蛋白質(glucose-6-phosphate;G6P)M9 培養基生長較差。而在使用次世代定序(Next generation sequencing , NGS)技術分析後,得知CP02在glpT上距轉錄起始位置(Transcription start site)第+865個位置被一跳躍子(Transporson)插入,在uhpT上距轉錄起始位置第+287個位置有跳躍子插入;CP15在glpT第388-420個核苷酸有缺失情形;在uhpA、uhpB、uhpC、uhpT上皆有缺失。另外將抗藥性菌株上所帶有表現GlpT D274V的glpT及表現UhpC A393V的uhpC置換於磷黴素感受性菌株NTUH-K2044上測定MIC變化,發現NTUH-K2044菌株MIC從64 μg/ml上升至1024 μg/ml,上升了約16倍,顯示此兩基因可能為造成磷黴素抗藥性的機制。 | zh_TW |
dc.description.abstract | Fosfomycin was used to treat urinary tract infection in early time, and it has been rarely used recently. Nowadays due to the ravages of multidrug resistant bacteria and the third-line antibiotic become less effect, fosfomycin combined with other antibiotics was chosen as new treatments against multidrug resistant bacteria. However, it has been reported that the fosfomycin-resistant bacteria were isolated on clinical research, including Klebsiella pneumoniae. Our study focused on the 56 strains of carbapenem-resistant Klebsiella pneumoniae(CRKP) derived from Taipei Veterans General Hospital. At first, we screened the 56 strains with 256 μg/ml fosfomycin MH agar plate(Base on CLSI guideline, fosfomycin MIC≧256 μg/ml are resistant). Minimal inhibitory concentration(MIC) test from 0 to 2048 μg/ml fosfomycin MH agar plate was performed. 19 high fosfomycin- resistant strain(MIC≧1024 μg/ml)were found. Next, we analyzed the gene related with fosfomycin resistance of the 19 high fosfomycin-resistant CRKP. The results showed that 12 strains carried glycerol-3-phosphate transporter gene (glpT) mutation;9 strains carried glucose-6-phosphate transporter gene(uhpT) mutation;4 strains carried defect in genes encoding GlpT-related or UhpT-related regulatory protein defect. Furthermore, we evaluated the transporter function of those strains carrying transporter gene mutation by performing the GlpT/UhpT transporter functional assay and found 11 strains were poorly grown on glycerol-3-phosphate M9 agar plate and 10 strains were poorly grown on glucose-6-phosphate M9 agar plate. And the next generation sequencing results showed that CP02 had a transposon inserted at 865th position from the transcription start site on glpT. A transposon inserted at 287th position from the transcription start site on uhpT was also found ; 30 mer deletion on glpT and deletion on uhpA, uhpB, uhpC and uhpT was found in CP15. On the other hand, fosfomycin-susceptible strain-NTUH-K2044 transformed with gene expressing GlpT D274V and UhpC A393V carried on fosfomycin-resistant CRKP strains showed an increase of MIC to 1024 μg/ml, about 16-fold higher than non-transformants. The results indicated that both genes were involved in the mechanism mediating the fosfomycin resistance. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:51:47Z (GMT). No. of bitstreams: 1 U0001-0308202015014200.pdf: 4784795 bytes, checksum: 7a265d51d1770a72679c5cd3a9e8f72e (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員審定書 i 致謝 ii 中文摘要 iii Abstract v 目錄 vii 表目錄 ix 圖目錄 x 第一章、 緒論 1 1.1克雷伯氏肺炎桿菌(Klebsiella pneumoniae) 1 1.2多重抗藥性細菌的肆虐(The rage of multidrug-resistant bacteria;MDR-Bacteria ) 2 1.3超廣效β-內醯氨酶之克雷伯氏肺炎桿菌(Extended spectrum beta-lactamase Klebsiella pneumoniae;ESBL-KP) 3 1.4抗碳青黴烯類類抗生素的克雷伯氏肺炎桿菌(Carbapenem-resistant Klebsiella pneumoniae;CRKP) 4 1.5臨床治療克雷伯氏肺炎桿菌感染之用藥及其抗藥性(Treatment of K. pneumoniae infection and its antibiotic resistance) 5 1.6舊藥新用:磷黴素(Fosfomycin) 6 1.7對磷黴素抗藥性機轉說明(Antibiotic resistance mechanism of fosfomycin) 7 1.8目前臺灣之克雷伯氏肺炎桿菌對磷黴素抗藥性的情況(The fosfomycin resistance of K. pneumoniae in Taiwan ) 8 1.9研究動機(Aim) 9 第二章、材料與方法 10 2.1 材料 10 2.1.1. 菌株(strains) 10 2.1.2. 質體(plasmids) 10 2.1.3. 培養基(media) 10 2.1.4. 抗生素(antibiotic) 10 2.1.5. 引子(primer) 10 2.2 方法 11 2.2.1 抗生素感受性試驗(antimicrobial susceptibility test) 11 2.2.2 運輸蛋白質功能試驗(Transporter functional test) 11 2.2.3 抽細菌genome DNA 12 2.2.4 利用DNAzol抽取細菌genome DNA 13 2.2.5 聚合酶連鎖反應(Polymerase chain reaction;PCR) 14 2.2.6 胺基酸置換(amino acid substitution) 14 2.2.7 噬菌體放大( Phage amplification ) 15 2.2.8 莢膜血清型定型實驗( Capsular typing ) 15 第三章、實驗結果 16 3.1 CRKP 對磷黴素最小抑菌濃度測試結果 16 3.2 19株對磷黴素高抗藥性的CRKP在磷黴素抗藥性相關基因分析 16 3.3 19株對磷黴素高抗藥性的CRKP莢膜分型結果 18 3.4 GlpT 運輸蛋白質功能試驗結果分析 18 3.5 UhpT 運輸蛋白質功能試驗結果分析 19 3.6 偵測表現GlpT D274V之基因置換於磷黴素感受性菌株NTUH-K2044後MIC變化結果 20 3.7 偵測表現UhpC A393V之基因置換於磷黴素感受性菌株NTUH-K2044後MIC變化結果 21 第四章、討論 22 第五章、參考文獻: 26 附錄 45 | |
dc.language.iso | zh-TW | |
dc.title | 運輸蛋白質在抗碳青黴烯類抗生素之克雷伯氏肺炎桿菌對於磷黴素高抗藥性之研究 | zh_TW |
dc.title | Transporters-mediated high level resistance mechanisms to fosfomycin in carbapenem-resistant Klebsiella pneumoniae | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 董馨蓮(SHIN-LIAN DOONG),林妙霞(MIAO-HSIA LIN) | |
dc.subject.keyword | 克雷伯氏肺炎桿菌,磷黴素,抗藥性, | zh_TW |
dc.subject.keyword | Klebsiella pneumoniae,fosfomycin,antibiotic resistance,GlpT,UhpT, | en |
dc.relation.page | 50 | |
dc.identifier.doi | 10.6342/NTU202002274 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
dc.date.embargo-lift | 2025-08-04 | - |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0308202015014200.pdf 目前未授權公開取用 | 4.67 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。